Ascendis Pharma A/S
Congressional Trades
| Politician | Stock | Type | Filed | Traded | |
|---|---|---|---|---|---|
Gary J. PalmerHouse · R · AL |
ASNDAscendis Pharma A/S · Stock |
Sale $1,001 - $15,000 |
Nov 7, 2018 | Oct 5, 2018 | Filing ↗ |
Gary J. PalmerHouse · R · AL |
ASNDAscendis Pharma A/S · Stock |
Purchase $1,001 - $15,000 |
Sep 29, 2018 | Aug 6, 2018 | Filing ↗ |
Gary J. PalmerHouse · R · AL |
ASNDAscendis Pharma A/S · Stock |
Purchase $1,001 - $15,000 |
Sep 29, 2018 | Jul 12, 2018 | Filing ↗ |
Whale Activity
- Increased138
- New74
- Held24
- Decreased89
- Closed40
- No prior filing17
| Filer | Shares | Value | Change |
|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 10.3M | $2.34B | held |
| T. Rowe Price Investment Management, Inc. | 8.2M | $1.87B | increased |
| WESTFIELD CAPITAL MANAGEMENT CO LP | 5.1M | $1.17B | increased |
| Avoro Capital Advisors LLC | 5.0M | $1.15B | decreased |
| Janus Henderson Group Ltd. | 3.6M | $828.5M | — |
| FMR LLC | 3.4M | $785.0M | decreased |
| WELLINGTON MANAGEMENT GROUP LLP | 3.1M | $699.5M | increased |
| BlackRock, Inc. | 2.3M | $520.4M | increased |
| Artisan Partners Limited Partnership | 2.1M | $474.6M | decreased |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 1.9M | $431.9M | increased |
| Capital International Investors | 1.4M | $322.9M | decreased |
| FRANKLIN TEMPLETON INC | 1.1M | $285.9M | decreased |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
Recent Insider Transactions
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| PEDERSEN ANNI LOTTE KIRSTINE SONDERBJERGEVP & Chief Admin Officer | Sale | −20.0K | $263.89 | $5.3M | Nov 17, 2026 | Form 4 ↗ |
| Bodenhoff MadsSVP & PAO | Sale | −3,000 | $270.19 | $811K | Sep 8, 2026 | Form 4 ↗ |
| Bodenhoff MadsSVP & PAO | Option exercise | +3,000 | $110.00 | $330K | Sep 8, 2026 | Form 4 ↗ |
| HOLTUG LARSDirector | Sale | −236 | $264.13 | $62K | Sep 2, 2026 | Form 4 ↗ |
| BIENAIME JEAN JACQUESDirector | Purchase | +900 | $246.91 | $222K | Aug 14, 2026 | Form 4 ↗ |
| BIENAIME JEAN JACQUESDirector | Purchase | +1,100 | $245.85 | $270K | Aug 14, 2026 | Form 4 ↗ |
| SMITH SCOTT THOMASEVP & Chief Financial Officer | Purchase | +100 | $219.00 | $22K | Jun 2, 2026 | Form 4 ↗ |
| BIENAIME JEAN JACQUESDirector | Purchase | +100 | $223.50 | $22K | May 29, 2026 | Form 4 ↗ |
| BIENAIME JEAN JACQUESDirector | Purchase | +200 | $222.30 | $44K | May 29, 2026 | Form 4 ↗ |
| BIENAIME JEAN JACQUESDirector | Purchase | +200 | $223.76 | $45K | May 29, 2026 | Form 4 ↗ |
| SMITH SCOTT THOMASEVP & Chief Financial Officer | Purchase | +250 | $223.32 | $56K | May 29, 2026 | Form 4 ↗ |
| BIENAIME JEAN JACQUESDirector | Purchase | +200 | $239.37 | $48K | May 26, 2026 | Form 4 ↗ |
| BIENAIME JEAN JACQUESDirector | Purchase | +200 | $236.24 | $47K | May 26, 2026 | Form 4 ↗ |
| JENSEN FLEMMING STEENSee Remarks | Sale | −19.5K | $238.49 | $4.6M | May 11, 2026 | Form 4 ↗ |
Fund Holders
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| Ultra Fund American Century Mutual Funds, Inc. | 664.0K | $162.0M | 0.63% | Jul 31, 2026 |
| Bridge Builder Small/Mid Cap Growth Fund Bridge Builder Trust | 473.3K | $126.2M | 1.13% | Jun 30, 2026 |
| T. Rowe Price Capital Appreciation Equity ETF T. Rowe Price Exchange-Traded Funds, Inc. | 350.1K | $93.4M | 1.26% | Jun 30, 2026 |
| Touchstone Strategic Trust-Touchstone Mid Cap Growth Fund Touchstone Strategic Trust | 313.9K | $83.7M | 3.68% | Jun 30, 2026 |
| LargeCap Growth Fund I Principal Funds, Inc | 310.4K | $75.7M | 1.33% | Jul 31, 2026 |
| Focused Dynamic Growth Fund American Century Growth Funds, Inc. | 213.8K | $52.2M | 2.61% | Jul 31, 2026 |
| iShares Russell 1000 Growth ETF iShares Trust | 179.6K | $47.9M | 0.04% | Jun 30, 2026 |
| International Equity Fund Principal Funds, Inc | 174.9K | $42.7M | 0.66% | Jul 31, 2026 |
| Bridge Builder Tax Managed Small/Mid Cap Fund Bridge Builder Trust | 112.0K | $29.9M | 0.84% | Jun 30, 2026 |
| VANGUARD RUSSELL 1000 GROWTH INDEX FUND VANGUARD SCOTTSDALE FUNDS | 76.5K | $20.1M | 0.04% | Aug 31, 2026 |
Mutual funds and ETFs whose N-PORT filings list ASND's shares (CUSIP K08588103), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
- T. Rowe Price Investment Management, Inc.SCHEDULE 13G/A · passive (13G) · 8.2M shares12.4%
Nov 16, 2026 · ↗ - Abigail P. JohnsonSCHEDULE 13G/A · passive (13G) · 3.4M shares5.2%
Nov 5, 2026 · ↗ - FMR LLCSCHEDULE 13G/A · passive (13G) · 3.4M shares5.2%
Nov 5, 2026 · ↗ - Artisan Partners Limited PartnershipSCHEDULE 13G/A · passive (13G) · 2.6M shares4.2%
Aug 13, 2026 · ↗ - Artisan Investments GP LLCSCHEDULE 13G/A · passive (13G) · 2.6M shares4.2%
Aug 13, 2026 · ↗ - Artisan Partners Holdings LPSCHEDULE 13G/A · passive (13G) · 2.6M shares4.2%
Aug 13, 2026 · ↗ - Artisan Partners Asset Management Inc.SCHEDULE 13G/A · passive (13G) · 2.6M shares4.2%
Aug 13, 2026 · ↗ - JANUS HENDERSON GROUP PLCSCHEDULE 13G/A · passive (13G) · 3.7M shares6.0%
May 15, 2026 · ↗ - Capital International InvestorsSCHEDULE 13G/A · passive (13G) · 2.0M shares3.2%
May 14, 2026 · ↗ - T. Rowe Price Investment Management, Inc.SCHEDULE 13G/A · passive (13G) · 6.5M shares10.5%
May 7, 2026 · ↗
Corporate Lobbying
No lobbying filings found naming Ascendis Pharma A/S as the client.
Government Contracts
No federal contract awards found for Ascendis Pharma A/S.
U.S. Patents
No USPTO patent applications found for Ascendis Pharma A/S.
Annual Financials
SEC's XBRL figures for Ascendis Pharma A/S include no full-year results from a 10-K in US dollars, so there is no table to show. Companies based abroad usually report annually on Form 20-F instead.
Stock Splits
No stock splits in ASND's price history.
Material Events (8-K)
No 8-K filings on record.

